Military Technology

DARPA wants to shine near-infrared light into people’s brains to activate, deactivate drugs in their bodies

DARPA is putting together a research program to shine near-infrared light into people’s brains that if successful, would be able to activate and deactivate drugs in their bodies on demand.

The US Defense Advanced Research Projects Agency (DARPA) put out a special notice for its Alert WARfighter Enablement (AWARE) program, which aims to help increase alertness following sleep loss in humans.

“The AWARE program aims to develop a combination drug and device to non-invasively increase alertness following sleep loss in humans, without negative side effects such as anxiety, irritability, or euphoria, and with reduced addictive potential”

DARPA AWARE Program Special Notice

American soldiers are often prescribed dextroamphetamine as a stimulant to help keep them alert following sleep deprivation, but the drug can cause anxiety, irritability, or euphoria, the latter of which can lead to addiction.

To counter this, DARPA is looking for a way to give soldiers a “photoswitchable” version of dextroamphetamine that remains inactive in the body until activated by the presence of near-infrared (NIR) light:

While active, the new photoswitchable drug behaves in the same manner as regular (i.e., non-photoswitchable) dextroamphetamine.”

Theoretically, the drug could be switched on or off with a flick of an NIR light shot into the head “to facilitate on-demand de-transition from alertness and make restorative sleep possible.”

And according to DARPA, “Temporal arrangement of NIR light pulses may be used to titrate the dose of activated drug over time, which can further reduce the potential for addiction and other undesirable effects.”

“The AWARE technology will be developed with temporal selectivity, enabling reversible activation of the drug precisely when needed”

DARPA AWARE Program Special Notice

The DARPA special notice describes the process as such:

“Through non-invasive delivery of NIR light to specific area(s) of the brain, the combination of photoswitchable drug and a NIR-emitting light will selectively activate regions of the prefrontal cortex responsible for executive function, working memory, and decision making, while avoiding deep brain structures such as the amygdala and striatum, which have been implicated in mood alterations and euphoria, respectively.”

Leading the AWARE program, should it become a fully-funded research project, will be Dr. Pedro Irazoqui, who, according to his bio, “joined DARPA in January 2024 as a program manager in the Biological Technologies Office. His research seeks to address the need for a more capable fighting force in extreme environments.”

As a full professor at Johns Hopkins University, Irazoqui’s “research is focused on the development of wearable and implantable wireless medical devices for treating diverse neural pathologies with a particular focus on epilepsy.”

The temporal selectivity of switching the drug from an active to inactive state is anticipated to facilitate on-demand de-transition from alertness and make restorative sleep possible

DARPA AWARE Program Special Notice

Last month, Neuroscience News highlighted a study from researchers at Massachusetts General Hospital showing how near-infrared light could help with traumatic brain injuries, PTSD, depression, and possibly even autism.

According to the Neuroscience News report:

Low-level light therapy aids brain healing in patients with moderate traumatic brain injury (TBI). Using a helmet that emits near-infrared light, researchers observed increased brain connectivity within two weeks of treatment.”

And according to a 2022 study in Frontiers in Pharmacology, near-infrared light “can penetrate transcranially the physical barriers of the skin and skull and reach the brain parenchyma if an optical window is used between 650 nm and 1,200 nm without excessive heat generation. Biomedical reports demonstrate the ability of NIR light to stimulate biochemical processes that maintain a healthy brain state and can be beneficial in acute and chronic pathologic brain conditions.”

The DARPA AWARE program is anticipated to comprise three phases over 36 months.


Image by vecstock on Freepik

Tim Hinchliffe

The Sociable editor Tim Hinchliffe covers tech and society, with perspectives on public and private policies proposed by governments, unelected globalists, think tanks, big tech companies, defense departments, and intelligence agencies. Previously, Tim was a reporter for the Ghanaian Chronicle in West Africa and an editor at Colombia Reports in South America. These days, he is only responsible for articles he writes and publishes in his own name. tim@sociable.co

Recent Posts

Do AI Agents Dream of Digital Langoustines?

The shift that matters for agent commerce - From “Crypto AI” to general AI Today,…

4 days ago

WEF CEO Brende resigns without mentioning Epstein connections

Daring not to speak his name, today's WEF press release left out any mention of…

5 days ago

Building tomorrow’s creators: Inside a 9 year old’s AI education vision

According to a recent report by McKinsey, most organizations today are already experimenting with or…

6 days ago

The push and pull: How and why the EU forced Apple to open iPhone app distribution (Brains Byte Back Podcast)

For more than a decade, launching an app on an iPhone meant playing by one…

1 week ago

Tony Colon brings decades of experience in customer innovation to the Senior Executive Board at Prezent 

Deloitte’s latest State of AI in the Enterprise, released in January of this year, captured…

1 week ago

Helogen’s HEL-IOS to turn Starlab into autonomous biomanufacturing hub in orbit 

As the space industry continues to expand, driving technological progress, economic growth and strategic advances,…

1 week ago